Annual Cash & Cash Equivalents
$3.85 M
-$9.40 M-70.98%
31 December 2023
Summary:
Akari Therapeutics annual cash & cash equivalents is currently $3.85 million, with the most recent change of -$9.40 million (-70.98%) on 31 December 2023. During the last 3 years, it has fallen by -$10.21 million (-72.64%). AKTX annual cash & cash equivalents is now -94.42% below its all-time high of $68.92 million, reached on 31 December 2015.AKTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$2.25 M
-$1.93 M-46.23%
01 September 2024
Summary:
Akari Therapeutics quarterly cash and cash equivalents is currently $2.25 million, with the most recent change of -$1.93 million (-46.23%) on 01 September 2024. AKTX quarterly cash and cash equivalents is now -97.15% below its all-time high of $78.77 million, reached on 30 September 2015.AKTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKTX Cash And Cash Equivalents Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -71.0% | - |
3 y3 years | -72.6% | -83.2% |
5 y5 years | -29.4% | -64.2% |
AKTX Cash And Cash Equivalents High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -72.6% | at low | -86.6% | +71.5% |
5 y | 5 years | -72.6% | at low | -86.6% | +71.5% |
alltime | all time | -94.4% | >+9999.0% | -97.2% | +71.5% |
Akari Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $2.25 M(-46.2%) |
June 2024 | - | $4.18 M(+218.9%) |
Mar 2024 | - | $1.31 M(-65.9%) |
Dec 2023 | $3.85 M(-71.0%) | $3.85 M(-46.5%) |
June 2023 | - | $7.18 M(-11.9%) |
Dec 2022 | $13.25 M(+41.5%) | - |
June 2022 | - | $8.15 M(-51.3%) |
Mar 2022 | - | $16.72 M(+78.6%) |
Dec 2021 | $9.36 M(-33.4%) | $9.36 M(-30.1%) |
Sept 2021 | - | $13.39 M(+253.2%) |
June 2021 | - | $3.79 M(-43.1%) |
Mar 2021 | - | $6.67 M(-52.6%) |
Dec 2020 | $14.06 M(+145.2%) | $14.06 M(+14.1%) |
Sept 2020 | - | $12.32 M(-3.4%) |
June 2020 | - | $12.75 M(+63.0%) |
Mar 2020 | - | $7.82 M(+36.5%) |
Dec 2019 | $5.73 M(+5.2%) | $5.73 M(-8.6%) |
Sept 2019 | - | $6.27 M(+129.1%) |
June 2019 | - | $2.74 M(-55.5%) |
Mar 2019 | - | $6.15 M(+12.8%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2018 | $5.45 M(-80.6%) | $5.45 M(-45.9%) |
Sept 2018 | - | $10.07 M(-33.2%) |
June 2018 | - | $15.07 M(-36.6%) |
Mar 2018 | - | $23.78 M(-15.4%) |
Dec 2017 | $28.11 M(-17.6%) | $28.11 M(+34.0%) |
Sept 2017 | - | $20.97 M(-30.4%) |
June 2017 | - | $30.12 M(+20.9%) |
Mar 2017 | - | $24.92 M(-26.9%) |
Dec 2016 | $34.10 M(-50.5%) | $34.10 M(+517.1%) |
Sept 2016 | - | $5.53 M(-42.8%) |
June 2016 | - | $9.66 M(-84.3%) |
Mar 2016 | - | $61.43 M(-10.9%) |
Dec 2015 | $68.92 M(+1971.2%) | $68.92 M(-12.5%) |
Sept 2015 | - | $78.77 M(+2798.2%) |
June 2015 | - | $2.72 M(-32.3%) |
Mar 2015 | - | $4.02 M(+20.7%) |
Dec 2014 | $3.33 M(-56.5%) | $3.33 M |
Dec 2013 | $7.66 M(+593.6%) | - |
Dec 2012 | $1.10 M(>+9900.0%) | - |
Dec 2011 | $6000.00 | - |
FAQ
- What is Akari Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akari Therapeutics?
- What is Akari Therapeutics annual cash & cash equivalents year-on-year change?
- What is Akari Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Akari Therapeutics?
What is Akari Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AKTX is $3.85 M
What is the all time high annual cash & cash equivalents for Akari Therapeutics?
Akari Therapeutics all-time high annual cash & cash equivalents is $68.92 M
What is Akari Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AKTX annual cash & cash equivalents has changed by -$9.40 M (-70.98%)
What is Akari Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AKTX is $2.25 M
What is the all time high quarterly cash and cash equivalents for Akari Therapeutics?
Akari Therapeutics all-time high quarterly cash and cash equivalents is $78.77 M